secwatch.observer — SEC 8-K summary
======================================

Issuer:     MESA LABORATORIES INC /CO/ (MLAB)
CIK:        0000724004
Form:       8-K
Filed at:   2022-03-30T23:59:59+00:00
Accession:  0001437749-22-007720
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Mesa files Agena financials post-acquisition; revises segment reporting structure
--------------------------------------------------------------------------------

- Agena's revenue for nine months ended Sep 30, 2021: $58.4M, up 45% YoY; net income of $12.8M vs loss of $0.38M.
- Mesa recast FY2021 segment data into four segments: Sterilization/Disinfection, Clinical Genomics (Agena), Biopharma Development, Calibration Solutions.
- Pro forma combined statement for nine months ended Dec 31, 2021 filed; acquisition closed Oct 20, 2021.
- Agena's cash and equivalents fell to $3.7M from $16.1M at Dec 31, 2020; debt repaid $22.5M during period.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/724004/000143774922007720/0001437749-22-007720-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/724004/000143774922007720/mlab20220309_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-22-007720

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer